Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
VectivBio logo — Biotech company develops treatments for severe rare diseases...

VectivBio

Biotech company develops treatments for severe rare diseases, aims to become global leader with patient-centric approach.

Founded 2019 Switzerland Basel, Switzerland 57 employees Acquired Total: $1.29B Biotechnology, Health Care

General Information

Company Name VectivBio
Founded Year 2019
Location Switzerland Basel, Switzerland
Founders / Decision Makers
Team member Team member Team member
Employees 57
Industries Biotechnology, Health Care
Funding Stage Acquired
Business Model B2B, B2D
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with VectivBio. To contact VectivBio, visit vectivbio.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does VectivBio compare?

A PDF of VectivBio and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting VectivBio soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About VectivBio

VectivBio is a Switzerland-based clinical-stage biotech company founded in 2019, focused on developing treatments for severe rare diseases. With a clear emphasis on a patient-centric approach, their mission is to address significant unmet medical needs by developing life-changing therapies.

The company boasts a skilled team with a proven track record in research, development, commercialization, and business growth. By aiming to become a global leader in the biotechnology and healthcare industries, VectivBio is committed to advancing novel therapies for orphan conditions with substantial medical requirements.

The company recently attracted a notable $1.00B acquisition investment from Ironwood Pharmaceuticals on 01 May 2023. This substantial investment underscores confidence in VectivBio's potential and strategic direction in the competitive biotech landscape.

Business keywords: Rare Diseases, Clinical-Stage Biotech, Patient-Centric Approach, Orphan Conditions, Drug Development, Therapy Commercialization, Innovative Medicines, Spinout Company, Translational Research, Life-Changing Therapies, Severe Illnesses, Targeted Therapies, Medical Needs

Services & Products

GI Treatment Advancement
Pharmaceutical Development
Patient Outcome Improvement
Research & Development

Target Customers

GI Patients Healthcare Providers Hospitals Medical Researchers

Funding Rounds & Investors (6)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $1.00B 1
Ironwood Pharmaceuticals
01 May 2023
Post-IPO Equity $54.00M 1
Forbion
Forbion
01 Jul 2022
Post-IPO Debt $75.00M 1
Kreos Capital
Kreos Capital
01 Mar 2022
IPO $24.23M -
01 Apr 2021
Early VC $110.00M 10
Novo Holdings Bpifrance OrbiMed
Novo Holdings, Bpifrance +8
01 Oct 2020
Early VC €31.00M 4
Novo Holdings OrbiMed Versant Ventures
Novo Holdings, OrbiMed +2
01 Jan 2020

VectivBio Alternatives & Competitors

View All Alternatives
VectivBio vs
Ultragenyx
Ultragenyx United States

Going Beyond Every Day

Post-IPO Equity
1535 employees
Biotechnology, Health Care
Compare VectivBio vs Ultragenyx
VectivBio vs
AAVantgarde
AAVantgarde

Pioneering treatments for Stargardt disease and Usher 1B, addressing the root cause of the disease

Series A
70 employees
Biotechnology, Health Care
Compare VectivBio vs AAVantgarde
VectivBio vs
Berlin Institute of Health in der Charité
Berlin Institute of Health in der Charité Germany

Aus Forschung wird Gesundheit

561 employees
Biotechnology, Health Care
View all alternatives

FAQ About VectivBio

Biotech company develops treatments for severe rare diseases, aims to become global leader with patient-centric approach.
VectivBio was founded in 2019.
VectivBio is headquartered in Basel, Switzerland.
VectivBio operates in Biotechnology and Health Care. Its work centres on Rare Diseases, Clinical-Stage Biotech, Patient-Centric Approach and Orphan Conditions. Its customers include GI Patients, Healthcare Providers and Hospitals.
VectivBio has a B2B and B2D business model. Its revenue comes from Product Sales and Licensing.
VectivBio has approximately 57 employees.
VectivBio has completed 6 funding rounds, raising a total of $1.29B. The latest funding stage is Acquired.
VectivBio offers: GI Treatment Advancement, Pharmaceutical Development, Patient Outcome Improvement, Research & Development.
Top alternatives and competitors to VectivBio include Ultragenyx, AAVantgarde, Berlin Institute of Health in der Charité, BridgeBio, NBE-Therapeutics AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
VectivBio and Ultragenyx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for VectivBio, https://bouncewatch.com/company/vectivbio, updated 27 January 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes